Drug profile · INN
mirikizumab
OMVOH
mirikizumab (OMVOH) is a interleukin-23 inhibitor.
EMA: approved PMDA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L04) L04AC
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — mirikizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.83
Quick answer
mirikizumab (OMVOH) is a interleukin-23 inhibitor.
Key facts
INN mirikizumab
Brand OMVOH
Mechanism Interleukin-23 inhibitor
Target Interleukin-23
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AC
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-23
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mirikizumab?
mirikizumab (OMVOH) is a interleukin-23 inhibitor.
What is the brand name for mirikizumab?
OMVOH is a marketed brand name for mirikizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.